What is Vertex Pharmaceuticals's debt securities, available-for-sale, unrealized loss position?

Vertex Pharmaceuticals (VRTX) reported debt securities, available-for-sale, unrealized loss position of $3.40B in Q1 2026.

Debt Securities, Available-for-Sale, Unrealized Loss Position

StatementBalance Sheet Statement

SectionOther

CategoryRisk

SignalLower is better

VolatilityModerate

First reportedQ4 2025

Last reportedQ1 2026

Higher values indicate greater sensitivity to market interest rate fluctuations and credit spread changes.

The total unrealized loss position for available-for-sale debt securities, reflecting the difference between amortized c...

Standard disclosure in the investment securities section of financial statements for banks.

Metric ID: other_debt_securities_available_for_sale_unrealized_loss_ab3ae9

1 periods

	Q1 '26
Value	$3.40B

What is Vertex Pharmaceuticals's debt securities, available-for-sale, unrealized loss position?: Vertex Pharmaceuticals (VRTX) reported debt securities, available-for-sale, unrealized loss position of $3.40B in Q1 2026.
What does debt securities, available-for-sale, unrealized loss position mean?: The total value difference for securities where the current price is below the purchase price.